文献速递乳腺癌

国际乳腺癌研究组TEXT和SOFT辅助内分泌治疗试验中35岁以下女性的治疗效果、依从性和生活质量

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
PubMed 文献 · J Clin Oncol · 2017-06-27

本文描述SOFT和TEXT试验中582例35岁以下乳腺癌患者辅助内分泌治疗的获益与毒性。SOFT中接受化疗后入组的240例HER2阴性35岁以下患者,5年无乳腺癌间期(BCFI)他莫昔芬单药为67.1%,他莫昔芬联合卵巢功能抑制(OFS)为75.9%,依西美坦联合OFS为83.2%;TEXT中145例HER2阴性35岁以下患者,他莫昔芬联合OFS的5年BCFI为79.2%,依西美坦联合OFS为81.6%。OFS最突出的生活质量症状为血管舒缩症状,6个月时较基线恶化约30至40分,性兴趣丧失和性唤起困难也具有临床意义(≥8分变化)。19.8%的35岁以下女性提前停止所有方案分配的内分泌治疗。

要点

  • 35岁以下HER2阴性乳腺癌患者,辅助OFS联合他莫昔芬或依西美坦较他莫昔芬单药大幅改善5年BCFI。
  • OFS最突出的生活质量症状为血管舒缩症状,6个月时较基线恶化约30至40分。
  • 19.8%的35岁以下女性提前停止所有方案分配的内分泌治疗。

核心结论

  • 在35岁以下激素受体阳性乳腺癌女性中,辅助OFS联合他莫昔芬或依西美坦较他莫昔芬单药大幅改善BCFI。
  • 更年期症状显著,但不比年长绝经前女性更严重。

研究设计与样本

  • SOFT试验中,术后仍处于绝经前状态的女性(接受或未接受化疗)被随机分配至他莫昔芬单药、他莫昔芬联合OFS或依西美坦联合OFS。
  • TEXT试验中,所有患者均接受OFS(联合或不联合化疗),并被随机分配至依西美坦联合OFS或他莫昔芬联合OFS。
  • 本文总结SOFT和TEXT中35岁以下女性队列(n=582)的治疗效果、生活质量和依从性,并与年长绝经前女性队列数据并列。

主要发现

  • SOFT中接受化疗后入组的240例HER2阴性35岁以下患者,5年BCFI他莫昔芬单药为67.1%(95%CI 54.6%至76.9%),他莫昔芬联合OFS为75.9%(95%CI 64.0%至84.4%),依西美坦联合OFS为83.2%(95%CI 72.7%至90.0%)。
  • TEXT中145例HER2阴性35岁以下患者,5年BCFI他莫昔芬联合OFS为79.2%(95%CI 66.2%至87.7%),依西美坦联合OFS为81.6%(95%CI 69.8%至89.2%)。
  • 接受OFS的35岁以下患者最突出的生活质量症状为血管舒缩症状,6个月时较基线恶化最大(约30至40分),性兴趣丧失和性唤起困难也具有临床意义(≥8分变化)。
  • 年长绝经前女性的症状负担水平相似。
  • 19.8%的35岁以下女性提前停止所有方案分配的内分泌治疗。

关键数值与推荐

  • SOFT中240例HER2阴性35岁以下患者5年BCFI:他莫昔芬单药67.1%(95%CI 54.6%至76.9%),他莫昔芬联合OFS 75.9%(95%CI 64.0%至84.4%),依西美坦联合OFS 83.2%(95%CI 72.7%至90.0%)。
  • TEXT中145例HER2阴性35岁以下患者5年BCFI:他莫昔芬联合OFS 79.2%(95%CI 66.2%至87.7%),依西美坦联合OFS 81.6%(95%CI 69.8%至89.2%)。
  • OFS相关血管舒缩症状6个月时较基线恶化约30至40分;性兴趣丧失和性唤起困难≥8分变化。
  • 19.8%的35岁以下女性提前停止所有方案分配的内分泌治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2-negative patients younger than 35 years enrolled in SOFT after receiving chemotherapy, the 5-year breast cancer-free interval (BCFI) was 67.1% (95% CI, 54.6% to 76.9%) with tamoxifen alone, 75.9% with tamoxifen plus OFS (95% CI, 64.0% to 84.4%), and 83.2% with exemestane plus OFS (95% CI, 72.7% to 90.0%). For 145 human epidermal growth factor receptor 2-negative patients younger than 35 years in TEXT, 5-year BCFI was 79.2% (95% CI, 66.2% to 87.7%) with tamoxifen plus OFS and 81.6% (95% CI, 69.8% to 89.2%) with exemestane plus OFS. The most prominent quality of life symptom for patients younger than 35 years receiving OFS was vasomotor symptoms, with the greatest worsening from baseline at 6 months (on the order of 30 to 40 points), but loss of sexual interest and difficulties in becoming aroused were also clinically meaningful (≥ 8-point change). The level of symptom burden was similar in older premenopausal women. A total of 19.8% of women younger than 35 years stopped all protocol-assigned endocrine therapy early. Conclusion In women younger than 35 years with hormone receptor-positive breast cancer, adjuvant OFS combined with tamoxifen or exemestane produces large improvements in BCFI compared with tamoxifen alone. Menopausal symptoms are significant but are not worse than those seen in older premenopausal women.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Saha P, Regan MM, Pagani O, et al. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017. PMID: 28654365. doi:10.1200/JCO.2016.72.0946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。